APA (7th ed.) Citation

Wang, K., Pan, C., Xu, F., Tse, A. N., & Sheng, Y. (2025). Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies. British Journal of Clinical Pharmacology, 91(3), 748. https://doi.org/10.1111/bcp.16276

Chicago Style (17th ed.) Citation

Wang, Kun, Chaohsuan Pan, Fengyan Xu, Archie N. Tse, and Yucheng Sheng. "Comprehensive Population Pharmacokinetic Modelling of Sugemalimab, an Anti‐programmed Death‐ligand 1 (PD‐L1) Human Monoclonal Antibody, in Patients with Solid Tumours or Lymphomas Across Multiple Phase I–III Studies." British Journal of Clinical Pharmacology 91, no. 3 (2025): 748. https://doi.org/10.1111/bcp.16276.

MLA (9th ed.) Citation

Wang, Kun, et al. "Comprehensive Population Pharmacokinetic Modelling of Sugemalimab, an Anti‐programmed Death‐ligand 1 (PD‐L1) Human Monoclonal Antibody, in Patients with Solid Tumours or Lymphomas Across Multiple Phase I–III Studies." British Journal of Clinical Pharmacology, vol. 91, no. 3, 2025, p. 748, https://doi.org/10.1111/bcp.16276.